Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
Saved in:
Published in | Blood Vol. 140; no. Supplement 1; pp. 7284 - 7285 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
15.11.2022
|
Online Access | Get full text |
Cover
Loading…
ISSN: | 0006-4971 1528-0020 |
---|---|
DOI: | 10.1182/blood-2022-159665 |